Key result
Bone marrow AGTR1 mRNA expression was significantly higher in multiple myeloma patients compared to healthy controls (6.82% vs 1.17%, p=0.044) and positively correlated with plasma β2-microglobulin.
Why the study?
Angiotensin II promotes growth and angiogenesis via AGTR1 in certain tumors, but bone marrow AGTR1 expression and its relationship with angiogenesis and prognostic factors in multiple myeloma remained to be examined.
Case-Control (n=54)
No
Absolute Event Rate: 6.82% vs 1.17%
p-value: p=0.044
Increased bone marrow AGTR1 expression in multiple myeloma correlates with markers of angiogenesis and disease prognosis.
AGTR1 expression may mark disease burden in multiple myeloma; hypothesis-generating and should not yet change practice.
Objective: Angiotensin II promotes growth and angiogenesis via type 1 receptors (AGTR1) in certain tumors. In this study, we examine the bone marrow AGTR1 expression in multiple myeloma (MM) and its relationship with the regulation of angiogenesis and prognostic factors. Materials and Methods: mRNA levels of 39 MM patients and 15 healthy controls were analyzed with quantitative RT-PCR. Immunohistochemical staining of the tissue vascular endothelial growth factor (VEGF), CD34, and factor VIIIrAg (fVIIIrAg) was used to assess bone marrow angiogenesis. Results: mRNA levels when compared to other patients. Conclusion: expression was found positively correlated with plasma β2-microglobulin level and patients with increased AGTR1 expression showed increased bone marrow CD34 levels.
No takes yet. Share an insight, caveat, or question.
Saka et al. (2019) conducted a case-control in Multiple Myeloma (n=54). Bone marrow AGTR1 mRNA expression was significantly higher in multiple myeloma patients compared to healthy controls (6.82% vs 1.17%, p=0.044) and positively correlated with plasma β2-microglobulin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: